Buys DLJ, Zárate OA

Language: Spanish
References: 23
Page: 303-308
PDF size: 206.43 Kb.

ABSTRACT

Introduction: Genic expression profiles have classified breast carcinomas into estrogen receptor + (luminal A y B), normal breast-like (luminal C), HER-2/neu overexpressing, and basal-like groups, with the last two associated with poor outcomes. Triple negative breast carcinomas (TNBCs) are a group of primary breast tumors defined by lack of expression of hormone receptors and HER-2/neu and aggressive clinical behavior. Most TNBCs possess a basal cell phenotype (BCP).
Objective: To identify an immunohistochemical profile and correlate it with some typical morphological features found in BLBC.
Materials and methods: From May 2007 through February 2008, we collected all TNBCs and marked them with cytokeratin 5/6, EGFR, protein P63, CD117, Ki67 and P53. We assess some morphological features in these tumors, which included necrosis, nuclear grade, lymphoplasmacytic infiltrate, pattern of growth and margins of the tumor.
Results: We collected 54 TNBCs, 94.5% of them were positive for at least one of the used markers. Cytokeratin 5/6 expression was observed in 90.19% and CD117 expression was observed in only 45.65%. High grade nuclei (G3) were observed in 87.5% and the rest were G2. Tumoral necrosis was also present in 66.66%.
Conclusions: With these four antibodies (CK5/6, EGFR, protein P63 and CD117), we can accurately identify basal-like tumors; there are some morphological features that let us suspect a basal cell-like phenotype.

REFERENCES

1. Calderón-Garcidueñas AL, Ruiz-Flores P, Cerda-Flores RM, Barrera-Saldaña HA. Clinical follow-up of Mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. Salud Publica Mex 2005;47:110-5.

2. Nielsen TO, Hsu FD, Jensen K, Karaca G, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.

3. Fulford LG, Easton DF, Reis-Filho JS, Hanby A, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49:22-34.

4. Fadare O, Tavassoli FA. The phenotypic spectrum of basal- like brest cancers: A critical appraisal. Adv Anat Pathol 2007;14:358-73.

5. Fadare O, Yeh IT. Basal-like breast cancers. Pathol Case Rev 2007;123:143-53.

6. Perou CM, Sorlie T, Eisen MB, Asklen LA, et al. Molecular portraits of human breast tumors. Nature. 2000; 406:747-52.

7. Sorlie T, Perou CM, Tibshirani R, Aas T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.

8. Sorlie T, Tibshirani R, Parker J, Hastie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;14:8418-23.

9. Diaz LK, Cryns VL, Symmans F, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007;14:419-30.

10. Fulford LG, Reis-Filho J, Ryder K, Jones C, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4.

11. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinoma. Clin Cancer Res 2006;12:1533-9.

12. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007;7:134.

13. Livasy CA, Karaca G, Nanda R, Moore P, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.

14. Lerma E, Peiro G, Ramon T, Barnadas A, et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 2007;20:1200-07.

15. González CL, Medeiros LHJ, Jaffe ES. Composite lymphoma: A clinicopathologic analysis of nine patients with Hodgkin’s disease and B-cell non-Hodgkin’s lymphoma. Am J Clin Pathol 1991;96:81-9.

16. Moll R, Krepler R, Franke WW. Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation 1983;23:256-69.

17. Moll R, Franke WW, Volc-Platzer B, Krepler R. Different keratin polypeptides in epidermis and other epithelia of human skin: a specific cytokeratin of molecular weight 46,000 in epithelia of the pilosebaceous tract and basal cell epitheliomas. J Cell Biol 1982;95:285-95.

18. Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005;7:143-8.

19. Nagle RB, Bocker W, Davis JR, Heid HW, et al. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 1986;34:869-81.

20. Dairkee SH, Mayall BH, Smith HS, Hackett AJ. Monoclonal marker that predicts early recurrences of breast cancer. Lancet 1987;1:514.

21. van de Rijn M, Perou CM, Tibshirani R, Haas P, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.

22. Reis-Filho JS, Milanezi F, Steele D, Savage K, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21.

23. Vincent-Salomon A, Gruel N, Lucchesi C, Mac Grogan G, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007;9:R24.